Access to anti-retroviral drugs, male in Nigeria

Nigeria: Access to anti-retroviral drugs, male was 84.0% in 2024. ◆ Volatile

Latest (2024)
84.0%
Change on year
up 12.0%
World rank
36th
of 141 countries
All-time high
84.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Nigeria, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 1 %2004: 2 %2005: 3 %2006: 7 %2007: 8 %2008: 14 %2009: 18 %2010: 16 %2011: 18 %2012: 19 %2013: 24 %2014: 28 %2015: 31 %2016: 36 %2017: 39 %2018: 39 %2019: 46 %2020: 53 %2021: 60 %2022: 68 %2023: 75 %2024: 84 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Nigeria stood at 84.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 12.0% on the previous year and up 200.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Nigeria peaked at 84.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Nigeria 36th out of 141 countries with data for 2024, putting it in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Nigeria, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Nigeria, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 1.0%
2004 2.0% +100.0%
2005 3.0% +50.0%
2006 7.0% +133.3%
2007 8.0% +14.3%
2008 14.0% +75.0%
2009 18.0% +28.6%
2010 16.0% -11.1%
2011 18.0% +12.5%
2012 19.0% +5.6%
2013 24.0% +26.3%
2014 28.0% +16.7%
2015 31.0% +10.7%
2016 36.0% +16.1%
2017 39.0% +8.3%
2018 39.0% +0.0%
2019 46.0% +17.9%
2020 53.0% +15.2%
2021 60.0% +13.2%
2022 68.0% +13.3%
2023 75.0% +10.3%
2024 84.0% +12.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 5.3% 0.0% 18.0% 10
2010s 29.6% 16.0% 46.0% 10
2020s 68.0% 53.0% 84.0% 5

Countries ranked near Nigeria

  1. 34 Italy 85.0% compare
  2. 34 New Zealand 85.0% compare
  3. 36 Croatia 84.0% compare
  4. 36 Eswatini 84.0% compare
  5. 36 Kenya 84.0% compare

See the full ranking of 160 places →

More gender data for Nigeria

All data for Nigeria →

Frequently asked questions

What is access to anti-retroviral drugs, male in Nigeria?
Access to anti-retroviral drugs, male in Nigeria was 84.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Nigeria?
The highest recorded value was 84.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Nigeria?
The lowest recorded value was 0.0% in 2000.
How does Nigeria rank for access to anti-retroviral drugs, male?
Nigeria ranks 36th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Nigeria?
Over the last ten years it is up 200.0%. The long-run trend across the full record is volatile.
Where does this Nigeria data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Nigeria. Statizoid, drawing on UNAIDS estimates. Retrieved 12 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/nigeria/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/nigeria/">Access to anti-retroviral drugs, male in Nigeria</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.